嗜铬细胞瘤/副神经节瘤术前合并Takotsubo样心肌病的围手术期结局
本研究纳入3个高容量中心2006–2019年间37例术前合并Takotsubo样心肌病的嗜铬细胞瘤/副神经节瘤手术患者,中位年龄45岁,距Takotsubo样心肌病发作后2个月(1–4)手术,33例(89%)行腹腔镜手术。所有患者术前血流动力学稳定,围手术期无儿茶酚胺危象等严重并发症,严重并发症和死亡为零。系统综述纳入5项研究38例患者,其中28例延迟手术,术后1例死亡。结论认为血流动力学稳定的此类患者可安全择期手术。
要点
- 术前合并Takotsubo样心肌病的嗜铬细胞瘤/副神经节瘤患者,血流动力学稳定后可择期手术。
- 37例患者中33例(89%)行腹腔镜手术,围手术期无严重并发症和死亡。
- 术中79%(27/34)需血管活性药物,常用尼卡地平、艾司洛尔和/或去甲肾上腺素。
核心结论
- 血流动力学稳定的嗜铬细胞瘤/副神经节瘤合并Takotsubo样心肌病患者可安全择期手术,围手术期结局与无Takotsubo样心肌病者相似。
研究设计与样本
- 多中心回顾性队列研究,纳入2006–2019年3个高容量中心37例术前合并Takotsubo样心肌病的嗜铬细胞瘤/副神经节瘤手术患者。
- 系统综述纳入5项研究共38例术前有至少1次急性心力衰竭(考虑Takotsubo样心肌病)的嗜铬细胞瘤/副神经节瘤患者。
主要发现
- 37例患者中位年龄45岁,距Takotsubo样心肌病发作后中位2个月(1–4)手术,33例(89%)行腹腔镜手术。
- 所有患者术前血流动力学稳定,除1例外均至少使用1种降压药,术前中位收缩压120 mmHg(95–132)。
- 27/34(79%)患者术中需血管活性药物,包括尼卡地平(22例)、艾司洛尔(12例)和/或去甲肾上腺素(8例)。
- 围手术期无高血压危象、心律失常、肺水肿、心肌缺血或Takotsubo样心肌病等儿茶酚胺相关危及生命的并发症,严重并发症和死亡为零。
- 系统综述中28例延迟手术患者术后1例死亡。
临床怎么用
- 对此类患者应先使血流动力学稳定,再安排择期手术,术中备好血管活性药物。
局限性
- 回顾性研究,样本量较小(37例),系统综述纳入研究有限(5项研究38例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pheochromocytomas and paragangliomas can induce severe cardiovascular manifestations such as Takotsubo-like cardiomyopathy. What the perioperative outcomes are of patients presenting with pheochromocytomas/paragangliomas preceded by Takotsubo-like cardiomyopathy remains an unresolved question. METHODS: From 2006 to 2019, all patients who underwent surgery for pheochromocytomas/paragangliomas preceded by Takotsubo-like cardiomyopathy were included from 3 high-volume centers, with specific attention to perioperative hemodynamic instability and postoperative outcomes. RESULTS: Overall, 37 patients were included, with a median age of 45 years. Patients were operated on 2 months (1-4) after a Takotsubo-like cardiomyopathy episode; 33 (89%) had a laparoscopic approach. All those who underwent surgery presented in a hemodynamically stable situation. All except 1 of the pheochromocytomas/paragangliomas patients had at least 1 antihypertensive treatment at the time of surgery. The median preoperative systolic blood pressure in the Takotsubo-like cardiomyopathy group was 120 mm Hg (95-132). Overall, 27/34 (79%) of patients required vasoactive drugs during surgery with nicardipine (n = 22), esmolol (n = 12), and/or norepinephrine (n = 8). No patient presented a catecholamine-induced life-threatening complication such as hypertensive crisis, cardiac arrhythmias, pulmonary edema, cardiac ischemia, or Takotsubo-like cardiomyopathy in the perioperative period. Severe morbi-mortality was nil. The systematic review identified 5 studies including 38 pheochromocytomas/paragangliomas patients with at least 1 episode of acute heart failure considered as Takotsubo-like cardiomyopathy before surgery, of which 28 patients had delayed surgery with 1 postoperative death. CONCLUSION: Hemodynamically stabilized patients with pheochromocytomas/paragangliomas preceded by Takotsubo-like cardiomyopathy can be safely scheduled for an elective pheochromocytomas/paragangliomas surgery, with similar intra and postoperative outcomes as those without Takotsubo-like cardiomyopathy.
引用
- Hain É, Chamakhi A, Lussey-Lepoutre C, et al. Perioperative outcomes of pheochromocytoma/paraganglioma surgery preceded by Takotsubo-like cardiomyopathy. Surgery. 2022. PMID: 35589436. doi:10.1016/j.surg.2022.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。